Ipilimumab: Unleashing the power of the immune system through CTLA-4 blockade

Seminars in Oncology

Volumn 37, Issue 5, 2010, Pages 440-449

  Boasberg, Peter ^a   Hamid, Omid ^a   O'Day, Steven ^a  

^a Angeles Clinic and Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACARBAZINE; GLYCOPROTEIN GP 100; INDOLEAMINE 2,3 DIOXYGENASE; INFLIXIMAB; IPILIMUMAB; LOPERAMIDE; MESSENGER RNA; METHYLPREDNISOLONE; TRANSCRIPTION FACTOR FOXP3;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; BRAIN METASTASIS; CANCER STAGING; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; COLITIS; DIARRHEA; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HORMONE SUBSTITUTION; HUMAN; IMMUNE RESPONSE; INTESTINAL BLEEDING; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER TOXICITY; MELANOMA; MONOTHERAPY; NAUSEA AND VOMITING; NONHUMAN; OVERALL SURVIVAL; PAIN; PATIENT COMPLIANCE; PRIORITY JOURNAL; RASH; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR BIOPSY; TUMOR VOLUME;

EID: 78449249018     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2010.09.004     Document Type: Article

References (70)

1. S.A. Rosenberg, J.C. Yang, S.L. Topalian, D.J. Schwartzentruber, J.S. Weber, and D.R. Parkinson Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose interleukin 2 JAMA 271 1994 907 913
2. T. Connerotte, A. Van Pel, and D. Godelaine Functions of anti-MAGE T-cells induced in melanoma patients under different vaccination modalities Cancer Res 68 2008 3931 3940
3. M.E. Dudley, J.R. Wunderlich, and J.C. Yang Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma J Clin Oncol 23 2005 2346 2357
4. D.L. Morton, L.J. Foshag, and D.S. Hoon Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine Ann Surg 216 1992 463 482
5. S. O'Day, F.S. Hodi, and D. McDermott A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma J Clin Oncol (Meeting Abstracts) 28 2010 4
6. F.S. Hodi, S. O'Day, and D. McDermott Ipilimumab immunotherapy alone or in combination with a peptide vaccine for pretreated, metastatic melanoma N Engl J Med 363 2010 711 723
7. G.Q. Phan, J.C. Yang, and R.M. Sherry Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma Proc Natl Acad Sci U S A 100; 2003 8372 8377
8. J.A. Gross, E. Callas, and J.P. Allison Identification and distribution of the costimulatory receptor CD28 in the mouse J Immunol 149 1992 380 388
9. P.S. Linsley, W. Brady, L. Grosmaire, A. Aruffo, N.K. Damle, and J.A. Ledbetter Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation J Exp Med 173 1991 721 730
10. M.L. Alegre, K.A. Frauwirth, and C.B. Thompson T-cell regulation by CD28 and CTLA-4 Nat Rev Immunol 1 2001 220 228
11. R.H. Schwartz A cell culture model for T lymphocyte clonal anergy Science 248 1990 1349 1356
12. T. Lindsten, K.P. Lee, and E.S. Harris Characterization of CTLA-4 structure and expression on human T cells J Immunol 151 1993 3489 3499
13. T.L. Walunas, D.J. Lenschow, and C.Y. Bakker CTLA-4 can function as a negative regulator of T cell activation Immunity 1 1994 405 413
14. L. Fong, and E.J. Small Anticytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment J Clin Oncol 26 2008 5275 5283
15. T.L. Walunas, C.Y. Bakker, and J.A. Bluestone CTLA-4 ligation blocks CD28-dependent T cell activation J Exp Med 183 1996 2541 2550
16. M.F. Krummel, and J.P. Allison CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells J Exp Med 183 1996 2533 2540
17. M.C. Brunner, C.A. Chambers, F.K. Chan, J. Hanke, A. Winoto, and J.P. Allison CTLA-4-mediated inhibition of early events of T cell proliferation J Immunol 162 1999 5813 5820
18. R.J. Greenwald, M.A. Oosterwegel, and D. van der Woude CTLA-4 regulates cell cycle progression during a primary immune response Eur J Immunol 32 2002 366 373
19. A.V. Maker, P. Attia, and S.A. Rosenberg Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade J Immunol 175 2005 7746 7754
20. D.R. Leach, M.F. Krummel, and J.P. Allison Enhancement of antitumor immunity by CTLA-4 blockade Science 271 1996 1734 1736
21. E.M. Sotomayor, I. Borrello, E. Tubb, J.P. Allison, and H.I. Levitsky In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance Proc Natl Acad Sci U S A 96 1999 11476 11481
22. A. van Elsas, R.P. Sutmuller, and A.A. Hurwitz Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy J Exp Med 194 2001 481 489
23. E.D. Kwon, B.A. Foster, and A.A. Hurwitz Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy Proc Natl Acad Sci U S A 96 1999 15074 15079
24. A. van Elsas, A.A. Hurwitz, and J.P. Allison Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing bacines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation J Exp Med 190 1999 355 366
25. A.A. Hurwitz, B.A. Foster, and E.D. Kwon Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade Cancer Res 60 2000 2444 2448
26. R.P. Sutmuller, L.M. van Duivenvoorde, and A. van Elsas Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses J Exp Med 194 2001 823 832
27. K. Ko, S. Yamazaki, and K. Nakamura Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells J Exp Med 202 2005 885 891
28. H. Schneider, J. Downey, and A. Smith Reversal of the TCR stop signal by CTLA-4 Science 29 2006 1972 1975
29. S. Tchekmedyian, J. Glaspy, A. Korman, T. Kele, Y. Deo, and T. Davis MDX-010 (human anti-CTLA-4): a phase I trial in malignant melanoma Proc Am Soc Clin Oncol (Meeting Abstracts) 21 2002 56
30. O. Hamid, W.J. Urba, and M. Yellin Kinetics of response to ipilimumab (MDX-010) in patients with stage III/IV melanoma J Clin Oncol (Meeting Abstracts) 25 2007 8525
31. J.S. Weber, E.M. Hersh, and M. Yellin The efficacy and safety of ipilimumab (MDX-010) in patients with unresectable stage III or stage IV malignant melanoma J Clin Oncol (Meeting Abstracts) 25 2007 8523
32. P. Attia, G.Q. Phan, and A.V. Maker Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4 J Clin Oncol 23 2005 6043 6053
33. J.S. Weber, S. O'Day, and W. Urba Phase I/II study of ipilimumab for patients with metastatic melanoma J Clin Oncol 26 2008 5950 5956
34. J. Weber, J.A. Thompson, and O. Hamid A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma Clin Cancer Res 15 2009 5591 5598
35. J.D. Wolchok, B. Neyns, and G. Linette Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study Lancet Oncol 11 2010 155 164
36. S.J. O'Day, M. Maio, and V. Chiarion-Sileni Efficacy and safety of ipilimumab in patients with pretreated advanced melanoma: a multicenter single-arm phase II study Ann Oncol 21 2010 1712 1717
37. E.L. Korn, P.Y. Liu, and S.J. Lee Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials J Clin Oncol 26 2008 527 534
38. Lebbe C, O'Day S, Hamid O, et al. The effect of HLA-A2 subtype on the efficacy and safety of ipilimumab in previously treated patients with advanced melanoma. Perepectives in Melanoma XIV, 2010, #0016.
39. A multi-center, randomized, double-blind, two-arm, phase III study in patients with untreated stage III (unresectable) or IV melanoma receiving dacarbazine plus 10 mg/kg ipilimumab (MDX-010) vs. dacarbazine with placebo. ClinicalTrials.gov Identifier: NCT00324155. Bristol-Meyers Squibb.
40. F.S. Hodi, S. O'Day, and D.F. McDermott Re-induction with ipilimumab, gp100 peptide vaccine, or a combination of both from a phase III, randomized, double-blind, multicenter study of previously treated patients with unresectable stage III or IV melanoma J Clin Oncol (Meeting Abstracts) 28 2010 8509
41. E.M. Hersh, J.S. Weber, and J.D. Powderly Disease control and long-term survival in chemotherapy-naive patients with advanced melanoma treated with ipilimumab (MDX- 010) with or without dacarbazine J Clin Oncol (Meeting Abstracts) 26 2008 9022
42. E.M. Hersh, S.J. O'Day, and J. Powderly A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-nave patients with advanced melanoma Invest New Drugs 2010 Jan 15
43. E. Hersh, J. Weber, and J. Powderly Long-term survival of patients (pts) with advanced melanoma treated with ipilimumab with or without dacarbazine J Clin Oncol (Meeting Abstracts) 27 2009 9038
44. J.G. Douglas, and K. Margolin The treatment of brain metastases from malignant melanoma Semin Oncol 29 2002 518 524
45. K. Margolin, B. Atkins, and A. Thompson Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group J Cancer Res Clin Oncol 128 2002 214 218
46. D.P. Lawrence, O. Hamid, and D.F. McDermott Phase II trial of ipilimumab monotherapy in melanoma patients with brain metastases J Clin Oncol (Meeting Abstracts) 28 2010 8523
47. N.E. Schartz, C. Farges, and I. Madelaine Complete regression of a previously untreated melanoma brain metastasis with ipilimumab Melanoma Res 20 2010 247 250
48. J.S. Weber, A. Sarnaik, and S. Targan Phase II trial of extended dose anti-CTLA-4 antibody ipilimumab (formerly MDX-010) with a multipeptide vaccine for resected stages IIIC and IV melanoma J Clin Oncol (Meeting Abstracts) 27 2009 9023
49. D.M. Berman, J. Wolchok, J. Weber, O. Hamid, S. O'Day, and S.D. Chasalow Association of peripheral blood absolute lymphocyte count (ALC) and clinical activity in patients (pts) with advanced melanoma treated with ipilimumab J Clin Oncol (Meeting Abstracts) 27 2009 3020
50. G.Y. Ku, J. Yuan, and D.B. Page Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival Cancer 116 2010 1767 1775
51. J.D. Lord, R.C. Hackman, and A. Moklebust Refractory colitis following anti-CTLA4 antibody therapy: analysis of mucosal FOXP3+ T cells Dig Dis Sci 55 2010 1396 1405
52. O. Hamid, S.D. Chasalow, and Z. Tsuchihashi Association of baseline and on-study tumor biopsy markers with clinical activity in patients (pts) with advanced melanoma treated with ipilimumab J Clin Oncol (Meeting Abstracts) 27 2009 9008
53. J.D. Wolchok, A. Hoos, and S. O'Day Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria Clin Cancer Res 15 2009 7412 7420
54. R.F. Little, J.M. Pluda, and K.M. Wyvill Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma Blood 107 2006 4650 4657
55. N. van Baren, M.C. Bonnet, and B. Drno Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells J Clin Oncol 23 2005 9008 9021
56. W.H. Kruit, H.H. van Ojik, and V.G. Brichard Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma Int J Cancer 117 2005 596 604
57. A.M. Di Giacomo, R. Danielli, and M. Guidoboni Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases Cancer Immunol Immunother 58 2009 1297 1306
58. J.D. Wolchok, A. Hoos, and S. O'Day Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria Clin Cancer Res 15 2009 7412 7420
59. F. Fadel, K.E. Karoui, and B. Knebelmann Anti-CTLA4 antibodyinduced lupus nephritis N Engl J Med 361 2009 211
60. G. Hunter, C. Voll, and C.A. Robinson Autoimmune inflammatory myopathy after treatment with ipilimumab Can J Neurol Sci 36 2009 518 520
61. R. Lin, M.J. Yellin, I. Lowy, A. Safferman, K. Chin, and R. Ibrahim An analysis of the effectiveness of specific guidelines for the management of ipilimumab-mediated diarrhea/colitis: prevention of gastrointestinal perforation and/or colectomy J Clin Oncol (Meeting Abstracts) 26 2008 9063
62. K.E. Beck, J.A. Blansfield, and K.Q. Tran Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4 J Clin Oncol 24 2006 2283 2289
63. D.R. Minor, K. Chin, and M. Kashani-Sabat Infliximab in the treatment of anti-CTLA4 (ipilimumab) induced immune-related colitis Cancer Biother Radiopharm 24 2008 321 325
64. A. Amin, V. DePril, and O. Hamid Evaluation of the effect of systemic corticosteroids for the treatment of immune-related adverse events (irAEs) on the development or maintenance of ipilimumab clinical activity J Clin Oncol (Meeting Abstracts) 27 2009 9037
65. C.S. Hinrichs, D.C. Palmer, S.A. Rosenberg, and N.P. Restifo Glucocorticoids do not inhibit antitumor activity of activated CD8+ T cells J Immunother 28 2005 517 524
66. F.O. Smith, S.L. Goff, and J.A. Klapper Risk of bowel perforation in patients receiving interleukin-2 after therapy with anti-CTLA 4 monoclonal antibody J Immunother 30 2007 130
67. J.A. Blansfield, K.E. Beck, and K. Tran Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer J Immunother 28 2005 593 598
68. K.C. Kaehler, F. Egberts, P. Lorigan, and A. Hauschild Anti-CTLA-4 therapy-related autoimmune hypophysitis in a melanoma patient Melanoma Res 19 2009 333 334
69. S.F. Slovin, T.M. Beer, and C.S. Higano Initial phase II experience of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration-resistant prostate cancer (mCRPC) J Clin Oncol (Meeting Abstracts) 27 2009 5138
70. T.J. Lynch, I.N. Bondarenko, and A. Luft Phase II trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line stage IIIb/IV non-small cell lung cancer (NSCLC) J Clin Oncol (Meeting Abstracts) 28 2010 7531